Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
ImpriMed, Inc.
What AI says about ImpriMed, Inc.
ImpriMed specializes in using artificial intelligence to analyze live cancer cells from dogs to predict the most effective chemotherapy drugs for treating lymphoma and leukemia. Their platform empowers veterinarians and pet owners to make informed treatment decisions quickly, enhancing the chances of successful outcomes.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Products & Services
ImpriMed Personalized Prediction Profile
AI-driven clinical outcome predictions for canine lymphoma and leukemia treatment.
ImpriMed Drug Response Predictions
Predictions on the likelihood of positive clinical responses to various anticancer drugs.
ImpriMed Immunoprofile
Provides diagnostic information for leukemia and lymphoma through flow cytometry.
ImpriMed Multidrug Sensitivity Genotyping (MDR1)
Genotyping service to assess drug sensitivity in canine patients.
Common Questions
What services does ImpriMed offer?
ImpriMed offers personalized prediction profiles, drug response predictions, immunoprofiles, and multidrug sensitivity genotyping specifically for canine lymphoma and leukemia.
How does ImpriMed's testing process work?
Veterinarians collect and send a sample of the dog's tumor and blood, which is then tested against various anticancer drugs to predict treatment effectiveness.
Who can order ImpriMed services?
ImpriMed services can only be ordered by licensed veterinarians.
What is the turnaround time for test results?
The turnaround time for most tests is between 2 to 7 days after the sample is received at the lab.
In which locations are ImpriMed services available?
ImpriMed services are currently offered in the United States, Canada, England, France, and South Korea.